Hypertrichosis of the eyelashes caused by bimatoprost

Tosti, Antonella; Pazzaglia, Massimiliano; Voudouris, Stylianos; Tosti, Giovanni

doi:10.1016/j.jaad.2004.05.002

Cited by 70 publications

(49 citation statements)

References 5 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This accounts for the slower onset of adverse events observed after travoprost application. 18,19 Interestingly, a deepening of the superior sulcus was observed in three cases including two that have been recently reported (Fig. 3).…”

Section: Discussionmentioning

confidence: 53%

“…4,16 On the other hand, the hyperpigmentation and hypertrichosis caused by travoprost developed earlier than those caused by latanoprost (7-15 months) and later than those caused by bimatoprost (1-2 months). 17,18 We suggest that this difference is probably due to the greater affi nity travoprost has for the FP receptor than latanoprost, owing to the presence of a fl uoromethylphenoxy group at carbon-17 in travoprost. 19 Unlike bimatoprost, which does not need to be converted to an active metabolite to have pharmacological activity, travoprost should be hydrolyzed by corneal esterase to a free fatty acid to activate the FP receptor.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma

2009

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 97%

Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma

2009

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] Recently, the use of biologics and laser therapy in alopecia areata have shown some beneficial results. [21][22][23] There has been a recent spurt in application of platelet-rich plasma (PRP) in dermatology and aesthetic medicine.…”

Section: Introductionmentioning

confidence: 99%

A clinical study on alopecia areata

Ninama¹,

Mahajan²,

Bilimoria³

et al. 2018

Int J Res Dermatol

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is a common auto-immune condition, causing hair loss. This disease has limited treatment modalities. Through this study, comparison between established modalities of treatment such as oral mini pulse therapy, intralesional corticosteroids and platelet-rich plasma (PRP) as a newer modality has been done. The objective of the study was to evaluate the efficacy and safety of various treatment modalities in alopecia areata.Methods: 45 patients with alopecia areata presenting to the OPD of Dermatology, Dhiraj hospital, Pipariya were included in this study. It was conducted as a randomized prospective study for a period of 16 weeks. After taking informed consent, patients were randomly distributed into three treatment groups. Group 1 patients were treated with Tab. Betamethasone 0.1 mg/kg every Saturday and Sunday, Group 2 was treated with Inj. Triamcinolone acetonide 10 mg/ml for scalp and 2.5 mg/ml for eye brows and face was injected into deep dermis; Group 3 was treated with Dermaroller followed by application of activated platelet rich plasma (PRP). SALT score was calculated at first visit and 16 weeks. Regrowth was calculated using Mac Donald and Null Horis grading Scale at 16 weeks.Results: The SALT score reduced from 13.27 to 7.52 in Group 1, 13.93 to 8.16 in Group 2 and 42.32 to 21.12 in Group 3. Mean grade of regrowth of hairs observed was 3.47, 3.80, 2.93 in Group 1, 2, 3 respectively. The results were analysed using paired t test.Conclusions:Intralesional corticosteroids viz. triamcinolone acetonide still remains the first choice of therapy for AA in adults with limited involvement. Systemic corticosteroids give lower response than intralesional steroids. Platelet Rich Plasma (PRP) showed promising results, especially in children and in extensive involvement. Compared to other treatment modalities Inj. PRP is safe and with less side effects.

show abstract

“…[251][252][253][254][255][256][257][258][259][260][261] The lashes may become thicker, longer, and increase in quantity (Fig. 51.10).…”

Section: Hypotensive Lipidsmentioning

confidence: 99%

Medications Used to Treat Glaucoma

Schacknow

Samples

2010

The Glaucoma Book

View full text Add to dashboard Cite

ConclusionOptimal therapy for glaucoma would involve IOP control throughout the 24-h period. However, not all therapies are equally efficacious at all times of the day and night. Understanding of the mechanisms of action of different therapies, along with the knowledge of the circadian changes in aqueous humor dynamics, allows us to predict the therapies that will provide the most consistent IOP reduction. As well, understanding of aqueous humor dynamics may help in the development of future therapies with consistent 24-h IOP control. Bibliography

show abstract

Hypertrichosis of the eyelashes caused by bimatoprost

Cited by 70 publications

References 5 publications

Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma

Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma

A clinical study on alopecia areata

Medications Used to Treat Glaucoma

Contact Info

Product

Resources

About